Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Mobocertinib

acf56bb5-1ccf-523a-9b94-b88ddb809363 · FDA Approval Withdrawn · targets EGFR

Mobocertinib

MeasuredReference

Mobocertinib targets EGFR, ERBB2_HER2, BLK. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

EGFRERBB2_HER2BLKERBB4_HER4BMX_ETK

Top hallmarks

  • tumor promoting inflammation2.5k
  • evading apoptosis1.9k
  • proliferation1.8k

Top pathways disrupted

  • allograft rejection4.8k
  • apical junction4.3k
  • pi3k akt mtor signaling4.0k

Resistance landscape — Mobocertinib

MeasuredReference

10 known oncogenic variants exist on Mobocertinib's top targets — see detail for inhibition impact.

Open in new tab